miR-145 inhibits mitochondrial function of ovarian cancer by targeting ARL5B

Shuo Zhao1, Yun Zhang2, Meili Pei3

  • 1Department of SICU, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Insights

MicroRNA-145 (miR-145) inhibits mitochondrial function in ovarian cancer by targeting ARL5B. This finding offers new insights into ovarian cancer

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Metabolic reprogramming, including glycolysis and mitochondrial metabolism, is crucial in cancer.
  • While miR-145's role in ovarian cancer glycolysis is known, its impact on mitochondrial metabolism remains unclear.

Purpose of the Study:

  • To investigate the role of miR-145 in mitochondrial metabolic reprogramming in ovarian cancer cells.

Main Methods:

  • Functional experiments involving miR-145 overexpression in ovarian cancer cells.
  • Assessment of mitochondrial function markers (mtDNA copy number, ATP level, membrane potential).
  • Mechanistic studies to identify miR-145 targets, including in vivo validation in mouse models.

Main Results:

  • Overexpression of miR-145 significantly inhibited mitochondrial function in ovarian cancer cells.
  • Key indicators of mitochondrial dysfunction included decreased mtDNA copy numbers, ATP levels, and mitochondrial membrane potential.
  • miR-145 was found to directly target ARL5B, and its overexpression reduced ARL5B levels in vitro and in vivo.

Conclusions:

  • miR-145 inhibits mitochondrial function in ovarian cancer by directly targeting ARL5B.
  • This study establishes miR-145 as a regulator of mitochondrial metabolic reprogramming in ovarian cancer.
  • The findings support miR-145 as a potential diagnostic and therapeutic target for ovarian cancer.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
17.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K